Key result
Pre-operative alvimopan reduces post-operative ileus duration, but high costs and logistics limit routine clinical use.
Why the study?
Does alvimopan improve intestinal motility and reduce the duration of post-operative ileus?
Does alvimopan improve intestinal motility and reduce the duration of post-operative ileus?
While alvimopan effectively reduces post-operative ileus, logistical barriers and high costs limit its routine clinical use.
Alvimopan is an US-FDA approved, peripherally acting mu opioid receptor antagonist which when started pre-operatively has been shown to hasten intestinal motility and reduce the duration of post-operative ileus. However the logistics involved in procuring, storing and dispensing the drug and the cost of the drug for fifteen doses as approved by FDA prohibits the use of it on a regular basis.
No takes yet. Share an insight, caveat, or question.
Abhijit Nair (2016) studied this question. Pre-operative alvimopan hastens intestinal motility and reduces post-operative ileus duration, but high costs and logistical challenges limit its regular clinical use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: